Dana Blankenhorn

Dana Blankenhorn

InvestorPlace Contributor

Expertise: Technology, Biotech, Renewable energy

Education: M.S,J. Northwestern (Medill School) 1978; B.A. Rice University, History and Political Science 1977

Awards & Accomplishments: Tech reporter since 1982, Freelance since 1983, on Internet since 1985. Created first online coverage of Internet with a magazine, Interactive Age, 1994 Co-wrote BBS Systems for Business in 1991, Wrote Guide to Field Computing in 1992 Wrote technology history now called "Living with Moore's Law" in 2001, 2010, 2021 Author of over a dozen books, both fiction and non-fiction

About Dana:
Dana Blankenhorn has been a financial journalist since 1978, a technology journalist since 1982, and an Internet journalist since 1985. He writes a Substack newsletter, Facing the Future, which covers technology, markets, and politics.

He has written a half-dozen technology books, several novels available at the Amazon Kindle store, and covered beats ranging from education to e-commerce, and from open source to renewable energy. He lives in Atlanta.

Recent Articles

Advanced Micro Devices Inc. Stock Still Is on the Chip Sector Battlefield

By Dana Blankenhorn, InvestorPlace Contributor

AMD faces a surging Nvidia in graphics, and the same problems as Intel with the Spectre flaw. The present looks brighter than the future.

Is Sanofi’s Bioverative Inc Buyout Just the Start?

By Dana Blankenhorn, InvestorPlace Contributor

Bioverativ and Juno Therapeutics both drew buyout bids as drug companies seek to use CAR-T therapy against cancer profitably.

Where Is Blockchain Heading? Your Questions Answered

By Dana Blankenhorn, InvestorPlace Contributor

No one really knows where blockchain is heading, including experts. Look for companies with second-mover advantage to find the most success.

Is International Business Machines Corp. Stock Still Worth a Look?

By Dana Blankenhorn, InvestorPlace Contributor

IBM stock remains dependent on its mainframe monopoly, as results in cloud, analytics and services disappointed in its quarterly report.

Celgene Corporation Stock Needs More Than a Juno Acquisition to Thrive

By Dana Blankenhorn, InvestorPlace Contributor

Celgene faces big risks in buying cancer drug candidates. The drug may fail late tests, or it might not get its price past insurers.

Load More